Literature DB >> 8969315

The consequence of production loss or increased costs of production.

M A Koopmanschap1, F F Rutten.   

Abstract

Mesh：

Year:  1996        PMID： 8969315

Source DB:  PubMed          Journal:  Med Care        ISSN： 0025-7079            Impact factor:   2.983


× No keyword cloud information.
  15 in total

1.  Household income losses associated with ischaemic heart disease for US employees.

Authors:  J Herrin; C B Cangialose; S J Boccuzzi; W S Weintraub; D J Ballard
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

Review 2.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 3.  Cost-of-illness studies. Useful for health policy?

Authors:  M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

4.  How to calculate indirect costs in economic evaluations.

Authors:  W B Brouwer; M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 5.  Employers' benefits from workers' health insurance.

Authors:  Ellen O'Brien
Journal:  Milbank Q       Date:  2003       Impact factor: 4.911

6.  The friction-cost method : replacement for nothing and leisure for free?

Authors:  Werner B F Brouwer; Marc A Koopmanschap
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  Transferability of indirect cost of chronic disease: a systematic review and meta-analysis.

Authors:  Fei-Li Zhao; Feng Xie; Hao Hu; Shu-Chuen Li
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

8.  Cost effectiveness of interventions for lateral epicondylitis: results from a randomised controlled trial in primary care.

Authors:  Ingeborg B C Korthals-de Bos; Nynke Smidt; Maurits W van Tulder; Maureen P M H Rutten-van Mölken; Herman J Adèr; Daniëlle A W M van der Windt; Willem J J Assendelft; Lex M Bouter
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Cost effectiveness and cost utility of acetylcysteine versus dimethyl sulfoxide for reflex sympathetic dystrophy.

Authors:  Hiske E M van Dieten; Roberto S G M Perez; Maurits W van Tulder; Jaap J de Lange; Wouter W A Zuurmond; Herman J Ader; Hindrik Vondeling; Maarten Boers
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Cost-benefit analysis of influenza vaccination in a public healthcare unit.

Authors:  Giorgio L Colombo; Antonio Ferro; Marta Vinci; Maria Zordan; Giulio Serra
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.